TIDMFDBK

RNS Number : 6679J

Feedback PLC

25 August 2021

Prior to publication, the information contained within this announcement was deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 ("MAR"). With the publication of this announcement, this information is now considered to be in the public domain.

Feedback plc

Change of Nominated Adviser and Broker

London, 25 August 2021 : Feedback plc (AIM: FDBK, "Feedback" or the "Company"), the specialist medical imaging technology and secure clinical communications company, is pleased to announce Panmure Gordon (UK) Limited has been appointed as the Company's Nominated Adviser and Sole Broker with immediate effect.

Dr Tom Oakley, CEO of Feedback, said: "In line with our strategy to drive clinical adoption of Bleepa both here in the UK and internationally, we are delighted to be working with Panmure Gordon, whose appointment, as industry specialists, signals a step change in our growth plans. We believe that their deep understanding of the sector, networks and broad institutional reach, will help us to progress our vision to enable clinicians to better securely communicate using everyday mobile technology, no matter their own location."

-Ends-

Enquiries:

 
 Feedback plc                               +44 (0)1954 718072 
  Tom Oakley, CEO                            IR@fbk.com 
  Lindsay Melvin, CFO 
 
 Panmure Gordon (UK) Limited (NOMAD 
  and Broker) 
  Emma Earl/Freddy Crossley (Corporate 
  Finance) 
  Rupert Dearden (Corporate Broking)        +44 (0)20 7886 2500 
 
 Walbrook PR Ltd                            Tel: 020 7933 8780 or feedbackplc@walbrookpr.com 
 Paul McManus/Nick Rome/Nicholas Johnson    07980 541 893 or 07748 325 236 or 
                                             07884 664 686

Notes to Editors

Feedback plc (AIM: FDBK) is a medical imaging technology business with a secure clinical communications platform. Its core product, Bleepa, is a revolutionary medical imaging communications app, providing an easy-to-use, high quality tool to enable remote and secure communications between front-line clinicians and teams. Importantly, it is the only CE marked medical imaging communications platform on the NHSx clinical communications tools framework. Bleepa has unparalleled functionality for everyday practice and can be accessed from any internet-connected device, enabling control of patient cases when on the go.

Its highly scalable Software as a Service ("SaaS") based revenue model will provide increasing levels of visibility as the Company grows its customer base. With a growing distribution base and technology in place, the focus is on leveraging key relationships in order to drive sales both in the UK and internationally to all forms of care providers. As a fully certified medical device, Bleepa aims to disrupt the medical imaging communications market and, importantly, increase the accuracy and speed of clinical review.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

APPEAEPLAEPFEAA

(END) Dow Jones Newswires

August 25, 2021 02:01 ET (06:01 GMT)

Feedback (LSE:FDBK)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Feedback Charts.
Feedback (LSE:FDBK)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Feedback Charts.